Association of neovascular age-related macular degeneration and hyperhomocysteinemia

被引:62
|
作者
Axer-Siegel, R
Bourla, D
Ehrlich, R
Dotan, G
Benjamini, Y
Gavendo, S
Weinberger, D
Sela, BA
机构
[1] Rabin Med Ctr, Dept Ophthalmol, IL-49100 Petah Tiqwa, Israel
[2] Chaim Sheba Med Ctr, Inst Chem Pathol, IL-52621 Tel Hashomer, Israel
[3] Tel Aviv Univ, Sackler Fac Med, IL-69978 Tel Aviv, Israel
[4] Tel Aviv Univ, Sackler Fac Exact Sci, Dept Stat, IL-69978 Tel Aviv, Israel
关键词
D O I
10.1016/S0002-9394(03)00864-X
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
PURPOSE: To assess the relationship between plasma homocysteine levels and exudative neovascular age-related macular degeneration (AMD). DESIGN: Cross-sectional study. METHODS: A prospective comparative cross,sectional study was conducted in outpatient ophthalmology clinics in a university affiliated medical institution. The cohort consisted of 59 patients (25 male, 34 female) with a mean age of 78 years (standard deviation [SD] = 8.4) with neovascular AMD who were candidates for photodynamic treatment. Patients were compared for plasma homocysteine levels with 58 patients who had dry AMD (24 male, 34 female) with a mean age of 76.3 years (SD = 8.4) and with a control group of 56 age,matched subjects (27 male, 29 female), with a mean age of 77.3 years (SD = 8.2). A 3,ml venous blood sample was obtained from each participant after an 8-hour fast. Levels of plasma homocysteine were measured by high performance liquid chromatography. The main outcome measure was hyperhomocysteinemia, defined as a plasma homocysteine level above 15 mumol/l. RESULTS: Homocysteine levels were higher by 27.9% in the neovascular AMD than in the dry AMD group, and by 21.9% than in the control group (P <.02). Hyperhomocysteinemia was found in 44. 1 % of the study group, in 22.4% of the dry AMD group, and in 21.4% of the control group (P = .0 11). CONCLUSIONS: This study suggests an association between an elevated plasma level of homocysteine and exudative neovascular AMD but not dry AMD.
引用
收藏
页码:84 / 89
页数:6
相关论文
共 50 条
  • [41] Systemic Changes in Neovascular Age-Related Macular Degeneration
    Singh, Amardeep
    DANISH MEDICAL JOURNAL, 2014, 61 (06):
  • [42] Abicipar pegol for neovascular age-related macular degeneration
    Hussain, Rehan M.
    Weng, Christina Y.
    Wykoff, Charles C.
    Gandhi, Raya A.
    Hariprasad, Seenu M.
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2020, 20 (09) : 999 - 1007
  • [43] The molecular mechanisms of neovascular age-related macular degeneration
    Miller, DW
    Joussen, AM
    Holz, FG
    OPHTHALMOLOGE, 2003, 100 (02): : 92 - 96
  • [44] Ranibizumab for neovascular age-related macular degeneration - Reply
    Rosenfeld, Philip J.
    Brown, David M.
    Schneider, Susan
    NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (07): : 749 - 750
  • [45] Review of Fibrosis in Neovascular Age-Related Macular Degeneration
    Cheong, Kai Xiong
    Cheung, Chui Ming Gemmy
    Teo, Kelvin Yi Chong
    AMERICAN JOURNAL OF OPHTHALMOLOGY, 2023, 246 : 192 - 222
  • [46] Differential diagnosis of neovascular age-related macular degeneration
    Engelbert, Michael
    SPEKTRUM DER AUGENHEILKUNDE, 2018, 32 (01) : 12 - 17
  • [47] Bevacizumab for the Treatment of Neovascular Age-Related Macular Degeneration
    Pitlick, Jamie M.
    Vecera, Kayla F.
    Barnes, Kylie N.
    Reski, John W.
    Forinash, Alicia B.
    ANNALS OF PHARMACOTHERAPY, 2012, 46 (02) : 290 - 296
  • [48] ` Early Insight Into Neovascular Age-Related Macular Degeneration
    Dryja, Thaddeus P.
    JAMA OPHTHALMOLOGY, 2016, 134 (11) : 1281 - 1282
  • [49] Neovascular age-related macular degeneration - Potential therapies
    Chappelow, Aimee V.
    Kaiser, Peter K.
    DRUGS, 2008, 68 (08) : 1029 - 1036
  • [50] An update on the pharmacotherapy of neovascular age-related macular degeneration
    Freund, K. Bailey
    Mrejen, Sarah
    Gallego-Pinazo, Roberto
    EXPERT OPINION ON PHARMACOTHERAPY, 2013, 14 (08) : 1017 - 1028